ELISA of IgG antibody to oxidized low-density lipoprotein: effects of blocking buffer and method of data expression.

We describe an ELISA for serum IgG antibodies against malondialdehyde-modified low-density lipoprotein (mLDL). Optimal antigen concentration, serum dilution, and dilution of enzyme-conjugated second antibody were 25 mg/L, 1:250, and 1:5000, respectively, when 5 g/L human serum albumin was used for blocking. When data were expressed as mLDL/LDL (the ratio of IgG binding to mLDL vs LDL), within-run and between-run CVs were 7.0% and 8.9%, respectively. Antibody concentrations expressed as mLDL/LDL or as mLDL-LDL (the difference between IgG binding to mLDL and to LDL) were higher in women with systemic lupus erythematosus (n = 20) than in controls (n = 20) (P < 0.001). With bovine serum albumin or Superblock blocking buffers, only the mLDL-LDL data were significant. Thus, the choice of blocking agent and the method of data expression should be carefully considered when assaying IgG antibodies against mLDL.

[1]  R. Ritchie,et al.  Background staining in immunoblot assays. Reduction of signal caused by cross-reactivity with blocking agents. , 1993, Journal of immunological methods.

[2]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[3]  M. Stringer,et al.  Lipid peroxides and atherosclerosis. , 1989, BMJ.

[4]  J L Witztum,et al.  Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. , 1990, Arteriosclerosis.

[5]  J. Beaumont,et al.  Immunoglobulin-bound lipoproteins (Ig-Lp) as markers of familial hypercholesterolemia, xanthomatosis and atherosclerosis. , 1988, Atherosclerosis.

[6]  D. Leake,et al.  The effect of EDTA on the oxidation of low density lipoprotein. , 1992, Atherosclerosis.

[7]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[8]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[9]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[11]  A. Chait.  Methods for assessing lipid and lipoprotein oxidation , 1992 .

[12]  D. Brown,et al.  Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. , 1990, Archives of pathology & laboratory medicine.

[13]  S. Wong,et al.  Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. , 1987, Clinical chemistry.

[14]  G. Hughes,et al.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity. , 1987, Annals of the rheumatic diseases.

[15]  M. Lopes-Virella,et al.  Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers , 1993, International journal of clinical & laboratory research.

[16]  P. Edwards,et al.  Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. , 1980, Proceedings of the National Academy of Sciences of the United States of America.